nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2022, 06, v.41;No.416 626-630
疏肝理气消岩方联合化疗对晚期三阴性乳腺癌的影响
基金项目(Foundation): 安徽省重点研究与开发计划项目(编号:202004j07020056)
邮箱(Email):
DOI: 10.16295/j.cnki.0257-358x.2022.06.009
摘要:

目的:研究自拟疏肝理气消岩方联合表柔比星注射液+环磷酰胺注射液(EC)化疗方案对晚期三阴性乳腺癌的影响。方法:选取60例晚期三阴性乳腺癌患者,按随机数字表法分为对照组和观察组各30例。对照组采用单纯EC方案化疗,观察组采用疏肝理气消岩方联合EC方案化疗,比较两组疗效,分析两组治疗前后血清肿瘤标志物糖类抗原153(CA-153)、糖类抗原125(CA-125)、癌胚抗原(CEA)变化,并对比两组不良反应发生情况及生活质量改善情况。结果:观察组有效率为65.52%,明显高于对照组的46.43%(P<0.05);两组治疗后血清CA-153、CA-125、CEA水平均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。观察组不良反应发生率为43.33%,明显低于对照组的76.68%(P<0.05)。观察组生活质量评分较对照组显著提高(P<0.05)。结论:疏肝理气消岩方联合化疗对晚期三阴性乳腺癌疗效明显,可有效改善血清肿瘤标志物水平,降低不良反应发生率,提高患者生活质量。

Abstract:

Objective:To study the effect of Shugan Liqi Xiaoyan Formula(疏肝理气消岩方) combined with epirubicin injection and cyclophosphamide injection(EC) chemotherapy on advanced three negative breast cancer. Methods:Total 60 patients with advanced three negative breast cancer were divided into the control group and the observation group according to the random number table method,with 30 cases in each group. The control group was treated with EC regimen alone,and the observation group was treated with Shugan Liqi Xiaoyan Formula combined with EC regimen. The effects of the two groups were compared,the changes of serum tumor markers carbohydrate antigen 153(CA-153),carbohydrate antigen 125(CA-125),carcinoembryonic antigen(CEA) before and after treatment were analyzed,and the occurrence of toxic and side effects and the improvement of quality of life were compared between the two groups. Results:The effective rate of the observation group was65.52%,which was significantly higher than 46.43% of the control group(P<0.05). The levels of CA-153,CA-125 and CEA in the two groups after treatment were lower than those before treatment(P<0.05). After treatment,the observation group were lower than those in the control group(P<0.05). The incidence of toxic and side effects in the observation group was 43.33%,which was significantly lower than 76.68% in the control group(P<0.05). The score of quality of life in the observation group was significantly higher than that in the control group(P<0.05). Conclusions:Shugan Liqi Xiaoyan Formula combined with chemotherapy have obvious effect on advanced three negative breast cancer,which can effectively improve the serum tumor markers level,reduce the incidence of toxic and side effects,and improve the quality of life.

参考文献

[1] GEBRESILLASSIE B M,GEBREYOHANNES E A,BELACHEW S A,et al. Evaluation of knowledge,perception,and risk awareness about breast cancer and its treatment outcome among university of gondar students,northwest ethiopia[J]. Front Oncol,2018,2(8):501-511.

[2]陈浩.华蟾素胶囊联合NX化疗方案对晚期乳腺癌患者血清肿瘤标志物及中位生存期的影响[J].河北医学,2019,25(3):533-537.

[3]李伟杰,白洁,谢贤鑫,等.中性粒细胞与淋巴细胞比值对三阴性乳腺癌临床预后及与Ki-67表达的影响[J].现代预防医学,2020,47(12):2287-2291,2304.

[4]石志强,邱鹏飞,刘雁冰,等. HER2阳性和三阴性乳腺癌新辅助化疗后选择性避免腋窝手术分期的研究[J].中国癌症杂志,2020,30(3):186-191.

[5]赵瑞娟,徐力.徐力治疗三阴乳腺癌经验[J].山东中医药大学学报,2014,38(3):237-239.

[6]周斌,季科,辛灵,等.美国肿瘤联合会乳腺癌分期系统(第8版)更新内容介绍及解读[J].中国实用外科杂志,2017,37(1):10-14.

[7]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):692-754.

[8]国家中医药管理局.中医病证诊断疗效标准:ZY/T001.1-94[S].南京:南京大学出版社,1994:201-202.

[9]杨学宁,吴一龙.实体瘤治疗疗效评价标准———RECIST[J].循证医学,2004,4(2):85-90,111.

[10]刘静,陆德铭.中医药治疗三阴性乳腺癌的临床研究进展[J].山东中医杂志,2016,35(11):1015-1017.

[11]吕梦玉,刘燕,农丽,等.中药复方联合化疗在晚期乳腺癌中的治疗进展[J].广西医科大学学报,2020,37(1):149-153.

[12]刘颖,张子英,马丽杰.山慈菇抗乳腺癌的作用机制研究进展[J].现代药物与临床,2019,34(3):863-866.

[13]田苗苗,刘扬,刘树民.蒲公英治疗乳腺癌的活性成分及作用机制研究概况[J].中国药房,2019,30(13):1864-1867.

[14]阮立为,邓甬川.消癌平对乳腺癌新辅助化疗疗效的增强作用及其机制探讨[J].中国中药杂志,2015,40(4):749-752.

[15] GUPTA S K,KUMAR V,ANEES A,et al. The study of prognostic significance of CA 15-3 in breast cancer[J].Int Surg J,2018,5(2):580.

[16]李丹,蓝兰,陈盼,等.中药预防性保肝对乳腺癌化疗所致药物性肝损伤的临床观察[J].中国基层医药,2017,24(5):698-701.

[17] WEN H N,GE M J,YAO D,et al. A simple method to identify undiagnosed drug-induced liver injury(DILI)and its application in oncology pharmacy practice[J].J Oncol Pharm Pract,2020,26(5):1060-1069.

[18]胡萌萌,姚昶,卞卫和.中医药辨治乳腺癌的思路初探[J].山东中医药大学学报,2018,42(4):305-307.

[19]唐小凡,徐文.不同提取工艺对泌尿宁颗粒中欧前胡素及五味子醇甲含量的影响[J].山东中医杂志,2018,37(4):334-337.

[20]于瑞,王建茹,彭广操,等.中药注射液防治蒽环类药物所致心脏毒性的系统评价[J].中草药,2021,52(10):3051-3060.

[21]王峰,王立新,刘芳茹,等.基于网络药理学探讨黄芪太子参药对减轻蒽环类药物心脏毒性的作用机制[J].中医杂志,2021,62(11):994-1000.

基本信息:

DOI:10.16295/j.cnki.0257-358x.2022.06.009

中图分类号:R737.9

引用信息:

[1]田平,李永安,宣小山.疏肝理气消岩方联合化疗对晚期三阴性乳腺癌的影响[J],2022,41(06):626-630.DOI:10.16295/j.cnki.0257-358x.2022.06.009.

基金信息:

安徽省重点研究与开发计划项目(编号:202004j07020056)

检 索 高级检索